Idiopathic generalised epilepsy is a group of brain disorders where seizures happen without any obvious brain injury or damage. For people with this condition, treatment focuses on controlling seizures to protect quality of life, prevent injuries, and allow normal daily activities like work and education. The path forward combines medicines proven to work with new therapies being tested in research trials around the world.

How doctors help people control their seizures

When someone receives a diagnosis of idiopathic generalised epilepsy, the main goal is not to cure the condition—because current medicine cannot do that—but to manage it effectively. Treatment aims to stop seizures from happening, or at least reduce how often and how severely they occur. By keeping seizures under control, people can live fuller lives with fewer risks of injury and better mental wellbeing. The brain in someone with idiopathic generalised epilepsy looks normal on scans and works normally between seizures, but episodes of abnormal electrical activity cause different types of seizures including brief losses of awareness, sudden muscle jerks, or dramatic convulsions where someone falls and shakes.^[1]

Treatment plans are highly individual because idiopathic generalised epilepsy is not one single disease—it includes several different syndromes like childhood absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with only generalised tonic-clonic seizures. Each subtype may start at a different age and respond differently to medicines. Some types that begin in childhood may gradually disappear as a person grows older, while others last a lifetime and require ongoing treatment.^[2][3]

Medical societies worldwide have published guidelines based on years of research and clinical experience. These guidelines help doctors choose the right medicine for each patient based on their seizure type, age, sex, and other health conditions. Importantly, some medicines that work well for other kinds of epilepsy can actually make seizures worse in people with idiopathic generalised epilepsy, so precise diagnosis is essential.^[5][8]

Standard medicines that form the backbone of treatment

For decades, doctors have successfully controlled seizures in most people with idiopathic generalised epilepsy using a category of drugs called antiseizure medicines (ASMs), also known as antiepileptic drugs. These medicines work by calming down the electrical storms that happen in the brain during a seizure. The challenge is finding the right medicine at the right dose for each individual person, because everyone responds differently.^[8]

Valproate, also known as valproic acid or sold under brand names like Depakote, has long been considered the most effective medicine for idiopathic generalised epilepsy. Studies show it works well for all the main seizure types seen in these conditions—absence seizures where someone briefly loses awareness, myoclonic seizures involving sudden muscle jerks, and tonic-clonic seizures where the person falls and convulses. Valproate affects brain chemicals and electrical signals to stabilise nerve cell activity. However, this medicine comes with serious concerns, especially for women who could become pregnant, because it has a high risk of causing birth defects and developmental problems in babies. For this reason, doctors try to avoid prescribing valproate to women of childbearing age unless no other option works.^[8][11]

Lamotrigine is another commonly prescribed medicine that many doctors prefer for women and girls because it is safer during pregnancy. It blocks channels in nerve cells that allow electrical signals to fire rapidly. Lamotrigine works particularly well for absence seizures and generalised tonic-clonic seizures, though it may be less effective for myoclonic jerks. The dose needs to be increased slowly over several weeks to avoid a potentially dangerous skin rash, one of its main side effects.^[11]

Levetiracetam, often known by the brand name Keppra, has become increasingly popular because it works reasonably well across different seizure types and has relatively few interactions with other medicines. It affects proteins in nerve cells that help control electrical signalling. Common side effects include mood changes, irritability, and tiredness, which some people find difficult to tolerate. The medicine is taken twice daily and can be adjusted relatively quickly compared to some other options.^[8][11]

Ethosuximide is a specialist medicine used specifically for absence seizures, particularly in children with childhood absence epilepsy. Research shows it ranks as one of the most effective options for this seizure type, though it does not work for other seizure types like myoclonic jerks or tonic-clonic seizures. Because of this limitation, some people need to take ethosuximide alongside another medicine if they have more than one seizure type. Side effects can include stomach upset, headache, and rarely blood disorders that require monitoring.^[11]

Topiramate is a broad-spectrum medicine that blocks several different channels and receptors in nerve cells. It can help with various seizure types in idiopathic generalised epilepsy. However, its side effects often limit its use—many people experience problems with memory and concentration, a condition informally called “brain fog,” as well as tingling in fingers and toes, weight loss, and kidney stones. These issues mean doctors often reserve topiramate for situations where other medicines have not worked.^[11]

Treatment typically continues for years, and many people need to take medicine for life. If someone has been completely seizure-free for two years or more, their doctor might consider slowly reducing the medicine dose to see if they can manage without it. However, this decision depends on many factors including the specific syndrome, brain wave patterns on tests, and the person’s lifestyle and preferences. Suddenly stopping seizure medicine can trigger dangerous clusters of seizures, so any changes must happen gradually under medical supervision.^[5]

Side effects vary widely between different medicines and between different people taking the same medicine. Common issues include tiredness, dizziness, weight changes, mood alterations, tremor, and problems with coordination. Some side effects fade after the first few weeks as the body adjusts, while others persist and may require switching to a different medicine. The goal is always to find the lowest effective dose that controls seizures while causing the fewest bothersome effects.^[8]

New approaches being explored in clinical trials

While established medicines work well for many people with idiopathic generalised epilepsy, around one in three people continue having seizures despite treatment, or they cannot tolerate the side effects of available medicines. This has driven researchers to test new treatments in clinical trials—carefully designed studies that test whether new therapies are safe and effective before they become widely available. These trials happen in phases, each with a specific purpose.^[8]

Phase I trials involve small groups of people and focus primarily on safety. Researchers carefully monitor what happens when people take different doses of a new medicine to identify the right dose range and watch for side effects. Phase II trials expand to more participants and begin measuring whether the treatment actually reduces seizures. Phase III trials involve hundreds or thousands of people and directly compare the new treatment against existing standard treatments or placebo (an inactive dummy treatment). Only after completing all these phases and proving both safety and effectiveness can a new medicine be approved for doctors to prescribe.^[1]

Several newer antiseizure medicines have completed clinical trials and gained approval for use in recent years, expanding options for people with idiopathic generalised epilepsy. Perampanel is one such medicine that works by blocking a specific type of receptor in nerve cells called AMPA receptors. These receptors normally allow nerve cells to become excited and fire electrical signals. By blocking them, perampanel reduces excessive electrical activity. Clinical trials showed that when added to existing treatment for people still having seizures, perampanel significantly reduced generalised tonic-clonic seizures and myoclonic seizures. Studies also suggest it has a favourable tolerability profile, meaning people experience fewer bothersome side effects compared to some other options. However, perampanel can cause dizziness, sleepiness, irritability, and falls, particularly at higher doses.^[11]

Another approach being studied involves medicines that affect GABA, which stands for gamma-aminobutyric acid, a chemical messenger in the brain that calms nerve cell activity. Several genes associated with idiopathic generalised epilepsy affect GABA receptors, suggesting that enhancing GABA’s calming effects might help control seizures. Some existing medicines already work through GABA systems, and researchers continue exploring new molecules that might work even better with fewer side effects.^[5]

Researchers are also investigating whether combinations of medicines might work better than single medicines for certain people. These adjunctive therapy trials test whether adding a second medicine to ongoing treatment can reduce seizures that persist despite taking a first medicine. For example, trials have shown that adding topiramate to existing treatment works particularly well for people with generalized tonic-clonic seizures, while adding levetiracetam helps most with myoclonic seizures. Understanding which combination works best for which seizure type allows doctors to tailor treatment more precisely.^[11]

Some clinical trials focus on understanding the genetic causes of idiopathic generalised epilepsy. Scientists have identified mutations in genes that control sodium channels, calcium channels, and GABA receptors in some families with epilepsy. This knowledge opens the possibility of precision medicine—choosing treatments based on a person’s specific genetic makeup rather than just their symptoms. While this approach is still largely experimental for epilepsy, it represents an exciting direction for future treatment.^[2][5]

Clinical trials for epilepsy take place in many countries, including specialized epilepsy centres across the United States, Europe, and other regions. People interested in participating usually need to meet specific requirements, such as having a confirmed diagnosis of a particular epilepsy syndrome, being within a certain age range, experiencing a minimum number of seizures per month, and being willing to keep detailed seizure diaries. Participation always involves informed consent, meaning researchers explain all the potential benefits and risks before someone agrees to take part. Many trials cover the cost of the treatment and related medical visits, though participants may need to travel to specific centres for appointments.^[1]

Beyond medicines, researchers are exploring other treatment approaches for people whose seizures cannot be controlled with medicines alone—a situation called drug-resistant epilepsy. However, surgery and device-based treatments developed for focal epilepsy generally do not work well for idiopathic generalised epilepsy because the seizures involve widespread areas of the brain on both sides rather than one specific spot that can be removed. This makes finding new medicine options even more important for people with difficult-to-control idiopathic generalised epilepsy.^[8]

Most common treatment methods

• Valproate therapy
  • Most effective single medicine for all seizure types in idiopathic generalised epilepsy including absence, myoclonic, and tonic-clonic seizures
  • Works by stabilising electrical activity in nerve cells through multiple mechanisms
  • Major concern about birth defects and developmental problems means doctors avoid using it in women who could become pregnant unless absolutely necessary
  • Often requires lifelong treatment for effective seizure control
• Lamotrigine therapy
  • Preferred option for women and girls of childbearing age due to better safety profile during pregnancy
  • Particularly effective for absence seizures and generalised tonic-clonic seizures
  • Requires slow dose increase over several weeks to reduce risk of serious skin rash
  • May be less effective for myoclonic seizures compared to other medicines
• Levetiracetam therapy
  • Broad-spectrum medicine that works reasonably well across different seizure types
  • Can be started and adjusted relatively quickly compared to some other medicines
  • Has few interactions with other medicines
  • Common side effects include mood changes, irritability, and tiredness
• Ethosuximide therapy
  • Specialist medicine used specifically for absence seizures, especially in children
  • Ranks as one of most effective treatments for childhood absence epilepsy
  • Does not work for myoclonic or tonic-clonic seizures, so may need to be combined with other medicines
  • Requires monitoring for rare blood disorders
• Adjunctive therapy with newer medicines
  • Adding a second medicine to ongoing treatment when first medicine alone does not control seizures
  • Topiramate added to existing treatment works particularly well for generalised tonic-clonic seizures
  • Levetiracetam as add-on therapy helps most with myoclonic seizures
  • Perampanel as adjunctive treatment reduces both tonic-clonic and myoclonic seizures with relatively good tolerability